Quality indicators related to the compliance of management with the standards of care
| QI 13 - Proportion of patients with a stage T1 disease treated by primary surgery who have undergone lymph node (LN) staging according to the ESGO-ESTRO-ESP guidelines | |
| Type | Outcome indicator |
| Description | Lymph nodes staging is defined according to the ESGO-ESTRO-ESP guidelines5–7 |
| Specifications |
Numerator: number of patients with a stage T1 disease who have undergone Lymph nodes staging according to the ESGO-ESTRO-ESP guidelines5–7
Denominator: all patients with a stage T1 disease who were treated by primary surgery |
| Target | ≥98% |
| QI 14 - Counseling about a possibility of FST | |
| Type | Structural indicator |
| Description | Counseling of patients with stage T1b1 ≤2 cm disease, potential candidates for fertility-sparing treatment, is described in the ESGO-ESTRO-ESP guidelines.5–7 All eligible patients should be appropriately counseled about a possibility of FST. FST should be undertaken exclusively in centers with comprehensive expertise in this management |
| Specifications |
Numerator: number of patients with stage T1b1 ≤2 cm disease, potential candidates for FST, counseled according to the ESGO-ESTRO-ESP guidelines5–7
Denominator: all patients with stage T1b1 ≤2 cm disease, potential candidates for FST |
| Target | 100% |
| QI 15 - Proportion of patients receiving adjuvant chemoradiotherapy after a primary surgical treatment for a stage pT1b1 pN0 disease | |
| Type | Structural indicator |
| Description | Management of patients after a surgical treatment for a stage pT1b1 pN0 disease is defined according to the ESGO-ESTRO-ESP guidelines5–7 |
| Specifications |
Numerator: number of patients receiving adjuvant chemoradiotherapy after primary surgical treatment for stage pT1b1 pN0 disease, according to the ESGO-ESTRO-ESP guidelines5–7
Denominator: all patients with primary surgical treatment for stage pT1b1 pN0 disease |
| Target | <15% |